Peter D'Andrea
- Once-daily QVA149 significantly improves lung function and symptoms compared to twice-daily fluticasone/salmeterol in COPD patients: The ILLUMINATE studyBy Claus Vogelmeier, Eric Bateman, John Pallante, Hannah Bryant, Vijay Alagappan, Peter D'Andrea, Ellie He and Donald BanerjiClaus Vogelmeier1Department for Respiratory Diseases, University of Marburg, Marburg, GermanyEric Bateman2Department of Medicine, University of Cape Town, South AfricaJohn Pallante3Respiratory Department, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHannah Bryant4Respiratory Department, Novartis Horsham Research Centre, Horsham, United KingdomVijay Alagappan4Respiratory Department, Novartis Horsham Research Centre, Horsham, United KingdomPeter D'Andrea3Respiratory Department, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesEllie He3Respiratory Department, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji3Respiratory Department, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK studyBy Marc Decramer, Jadwiga A. Wedzicha, Joachim H. Ficker, Angel FowlerTaylor, Peter D'Andrea, Christie Arrasate, Hungta Chen and Donald BanerjiMarc Decramer1Respiratory Division, University Hospitals, Leuven, BelgiumJadwiga A. Wedzicha2Centre for Respiratory Medicine, University College, London, United KingdomJoachim H. Ficker3Department of Respiratory Medicine, Allergology, and Sleep Medicine, Klinikum Nuernberg, Nuernberg, GermanyAngel FowlerTaylor4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesChristie Arrasate4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK studyBy Joachim H. Ficker, Jadwiga A. Wedzicha, Marc Decramer, Angel FowlerTaylor, Peter D'Andrea, Christie Arrasate, Hungta Chen and Donald BanerjiJoachim H. Ficker1Department of Respiratory Medicine, Allergology, and Sleep Medicine, Klinikum Nuernberg, Nuernberg, GermanyJadwiga A. Wedzicha2Centre for Respiratory Medicine, University College, London, United KingdomMarc Decramer3Respiratory Division, University Hospitals, Leuven, BelgiumAngel FowlerTaylor4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesChristie Arrasate4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Once-daily QVA149 has a good safety profile in patients with COPDBy Tobias Welte, Claus Vogelmeier, Ronald Dahl, Kenneth R. Chapman, Michael Rudolf, Rajendra Mehta, Peter D'Andrea, Hungta Chen and Donald BanerjiTobias Welte1Department of Respiratory Medicine, Hannover Medical School, Hanover, GermanyClaus Vogelmeier2Department of Respiratory Medicine, Universitätsklinikum Gießen Und Marburg, Marburg, GermanyRonald Dahl3Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, DenmarkKenneth R. Chapman4Asthma and Airway Center, University of Toronto, Toronto, CanadaMichael Rudolf5Department of Respiratory Medicine, Ealing Hospital, Middlesex, United KingdomRajendra Mehta6Allergy and Asthma Care, Allergy & Asthma Care and Research Centre, Indore, IndiaPeter D'Andrea7Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen7Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji7Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- QVA149 provides superior peak lung function in patients with COPDBy Neil Barnes, Shu Hashimoto, Takahide Nagase, Hungta Chen, Nicola Gallagher, Peter D'Andrea, Vijay Alagappan and Donald BanerjiNeil Barnes1Department of Respiratory Medicine, London Chest Hospital, London, United KingdomShu Hashimoto2Division of Respiratory Medicine, Nihon University School of Medicine, Tokyo, JapanTakahide Nagase3Department of Respiratory Medicine, University of Tokyo, Tokyo, JapanHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesNicola Gallagher5Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Once-daily QVA149 improves symptom scores in patients with COPDBy Tobias Welte, Ronald Dahl, Hungta Chen, Nicola Gallagher, Peter D'Andrea, Vijay Alagappan and Donald BanerjiTobias Welte1Department of Respiratory Medicine, Hannover Medical School, Hannover, GermanyRonald Dahl2Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, DenmarkHungta Chen3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesNicola Gallagher4Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomPeter D'Andrea3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- QVA149 does not increase the risk of cardio- and cerebro-vascular events, pneumonia and exacerbation events compared with placebo: A network meta-analysis across multiple safety databasesBy Hungta Chen, Peter D'Andrea and Donald BanerjiHungta Chen1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, United StatesPeter D'Andrea1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, United StatesDonald Banerji1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, United States
- Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trialsBy Donald Banerji, Vijay Alagappan, Yulia Green, Nicola Gallagher, Angel FowlerTaylor, Peter D'Andrea and Hungta ChenDonald Banerji1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesYulia Green2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomNicola Gallagher2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomAngel FowlerTaylor1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen1Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPDBy Ronald Dahl, Nicola Gallagher, Yulia Green, Hannah Bryant, Hungta Chen, Peter D'Andrea, Vijay Alagappan and Donald BanerjiRonald Dahl1Department of Respiratory Medicine, Aarhus University Hospital, Aarhus, DenmarkNicola Gallagher2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomYulia Green2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomHannah Bryant2Primary Care, Novartis Horsham Research Centre, Horsham, United KingdomHungta Chen3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesVijay Alagappan3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji3Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK studyBy Joachim H. Ficker, Jadwiga A. Wedzicha, Marc Decramer, Angel FowlerTaylor, Peter D'Andrea, Christie Arrasate, Hungta Chen and Donald BanerjiJoachim H. Ficker1Department of Respiratory Medicine, Allergology, and Sleep Medicine, Klinikum Nuernberg, Nuernberg, GermanyJadwiga A. Wedzicha2Centre for Respiratory Medicine, University College, London, United KingdomMarc Decramer3Respiratory Division, University Hospitals, Leuven, BelgiumAngel FowlerTaylor4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesChristie Arrasate4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Safety of once-daily glycopyrronium in patients with severe-to-very severe COPD: The SPARK studyBy Marc Decramer, Jadwiga A. Wedzicha, Joachim H. Ficker, Angel FowlerTaylor, Peter D'Andrea, Christie Arrasate, Hungta Chen and Donald BanerjiMarc Decramer1Respiratory Division, University Hospitals, Leuven, BelgiumJadwiga A. Wedzicha2Centre for Respiratory Medicine, University College, London, United KingdomJoachim H. Ficker3Department of Respiratory Medicine, Allergology, and Sleep Medicine, Klinikum Nuernberg, Nuernberg, GermanyAngel FowlerTaylor4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesChristie Arrasate4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Cardio- and cerebro-vascular safety of QVA149: Results from a pooled analysisBy Gary T. Ferguson, Neil Barnes, Rajendra Mehta, Peter D'Andrea, Hungta Chen and Donald BanerjiGary T. Ferguson1Pulmonology, Pulmonary Research Institute of Southeast Michigan, Livonia, United StatesNeil Barnes2Department of Respiratory Medicine, London Chest Hospital, Barts Health NHS Trust, London, United KingdomRajendra Mehta3Allergy and Asthma Care, Allergy & Asthma Care and Research Centre, Indore, IndiaPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, United StatesHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, United States
- Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK studyBy Jadwiga A. Wedzicha, Marc Decramer, Joachim H. Ficker, Angel FowlerTaylor, Peter D'Andrea, Christie Arrasate, Hungta Chen and Donald BanerjiJadwiga A. Wedzicha1Centre for Respiratory Medicine, University College London, London, United KingdomMarc Decramer2Respiratory Division, University Hospitals, Leuven, BelgiumJoachim H. Ficker3Department of Respiratory Medicine, Allergology, and Sleep Medicine, Klinikum Nuernberg, Nuernberg, GermanyAngel FowlerTaylor4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesPeter D'Andrea4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesChristie Arrasate4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesHungta Chen4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesDonald Banerji4Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
- Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS)By Robert Di Giovanni, Peter D'Andrea, Huilin Hu, Pankaj Goyal and Vikas JoshiRobert Di Giovanni1Primary Care, Novartis Pharma AG, Basel, SwitzerlandPeter D'Andrea2Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Huilin Hu2Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ,Pankaj Goyal1Primary Care, Novartis Pharma AG, Basel, SwitzerlandVikas Joshi3Medical Function, Novartis Healthcare Pvt. Ltd., Hyderabad, India
- Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPDBy James F. Donohue, Paul Jones, Christian Bartels, Jessica Marvel, Peter D'Andrea, Donald Banerji, Francesco Patalano and Robert FogelJames F. Donohue1Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC United StatesPaul Jones2Division of Clinical Science, St George's University of London, London, United KingdomChristian Bartels3Respiratory, Novartis Pharma AG, Basel, SwitzerlandJessica Marvel4Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United StatesPeter D'Andrea4Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United StatesDonald Banerji4Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United StatesFrancesco Patalano3Respiratory, Novartis Pharma AG, Basel, SwitzerlandRobert Fogel4Respiratory, Novartis Pharmaceuticals Corporation, East Hanover, NJ United States
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.